Topical pimecrolimus effect on Fas inducing apoptosis in oral lichen planus: A clinical immunohistochemical study

Journal of Oral Pathology and Medicine

Volumn 41, Issue 4, 2012, Pages 315-321

  Ibrahim, Suzan S ^a,b   Hazzaa, Hala H ^c  

^a Ain Shams University   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c Al Azhar University   (Egypt)

Author keywords

Apoptosis; Fas; Oral lichen planus; Pimecrolimus

Indexed keywords

CORTICOSTEROID; FAS LIGAND; PIMECROLIMUS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LICHEN PLANUS; MALE; ORAL LICHEN PLANUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD95; APOPTOSIS; CALCINEURIN; COLORING AGENTS; FEMALE; FOLLOW-UP STUDIES; GELS; GINGIVAL DISEASES; GLUCOCORTICOIDS; HEMATOXYLIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; OINTMENTS; PAIN MEASUREMENT; TACROLIMUS; TONGUE DISEASES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE;

EID: 84858698516     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01099.x     Document Type: Article

References (32)

1. Al-Hashimi I, Schifter M, Lockhart PB, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl): S25. e1-S25.12.
2. Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg 2008; 46: 15-21.
3. van der Meij EH, Mast H, van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol 2007; 43: 742-8.
4. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002; 46: 207-14.
5. van der Meij EH, Schepman KP, van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 164-71.
6. Khan A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003; 32: 77-83.
7. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 40-51.
8. Majorana A, Facchetti F, Pellegrini W, Sapelli P. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1999; 28: 47-8.
9. Al Johani KA, Hegarty AM, Porter SR, Fedele S. Calcineurin inhibitors in oral medicine. J Am Acad Dermatol 2009; 61: 829-40.
10. Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 2007; 143: 472-6.
11. Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med 2003; 32: 315-22.
12. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2: 175-84.
13. Chen Q, Luo G, Li B, Samaranayake LP. Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: a semi-quantitative immunohistochemical study. J Oral Pathol Med 1999; 28: 158-64.
14. Chen Q, Samaranayake LP, Zhen X, Luo G, Nie M, Li B. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis. Oral Oncol 1999; 35: 548-53.
15. Dekker NP, Lozada-Nur F, Lagenaur LA, MacPhail LA, Bloom CY, Regezi JA. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1997; 26: 170-5.
16. Bascones C, Gonzalez-Moles MA, Esparza G, et al. Apoptosis and cell cycle arrest in oral lichen planus Hypothesis on their possible influence on its malignant transformation. Arch Oral Biol 2005; 50: 873-81.
17. Kim SG, Chae CH, Cho BO, et al. Apoptosis of oral epithelial cells in oral lichen planus caused by upregulation of BMP-4. J Oral Pathol Med 2006; 35: 37-45.
18. Bascones-Ilundain C, González-Moles MA, Campo-Trapero J, et al. No differences in caspase-3 and Bax expression in atrophic-erosive vs. reticular oral lichen planus. J Eur Acad Dermatol Venereol 2008; 22: 204-12.
19. Carrozzo M, de Capei MU, Dametto E, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 2004; 122: 87-94.
20. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88: 969-73.
21. Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Bürger A, Stütz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003; 149: 853-7.
22. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407-10.
23. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142: 1066-7.
24. Dissemond J, Schröter S, Franckson T, Herbig S, Goos M. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol 2004; 150: 782-4.
25. Esquivel-Pedraza L, Fernández-Cuevas L, Ortíz-Pedroza G, Reyes-Gutiérrez E, Orozco-Topete R. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004; 150: 771-3.
26. Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol 2005; 76: 627-35.
27. Gorouhi F, Solhpour A, Beitollahi JM, et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007; 57: 806-13.
28. Volz T, Caroli U, Lüdtke H, et al. Pimecrolimus cream 1% in erosive oral lichen planus - a prospective randomized double-blind vehicle-controlled study. Br J Dermatol 2008; 159: 936-41.
29. Mattsson U, Magnusson B, Jontell M. Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: e19-25.
30. Berger TG, Duvic M, Voorhees AS, VanBeek MJ, Frieden IJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818-23.
31. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006; 6: 270-4.
32. Stern RS. Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol 2006; 142: 1233-5.